RxDoctor Payments Data

Michele Woodward

Family · Salem, INNPI 1124687611

Payments from drug & device makers

$721in general payments, 2019–2025

Across 47 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$91
  • Novartis$82
  • Johnson & Johnson$80
  • Amgen$77
  • Esperion Therapeutics, Inc.$66
  • Amarin Pharma, Inc.$66
  • plus $258 from 11 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$721 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$33,678
Medicare patients
117
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$55,139
TrulicityDulaglutide34$37,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$25,056
FarxigaDapagliflozin Propanediol18$17,289
MounjaroTirzepatide16$16,787
JanuviaSitagliptin Phosphate17$15,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,123
LinzessLinaclotide14$11,578
Spiriva RespimatTiotropium Bromide12$6,218
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen147$4,835
MovantikNaloxegol Oxalate11$4,693
Albuterol Sulfate HfaAlbuterol Sulfate113$2,025
SynthroidLevothyroxine Sodium45$1,863
Duloxetine Hcl74$1,484
LantusInsulin Glargine,hum.Rec.Anlog14$1,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$55,13959 claims
Lilly USA, LLCTrulicity, Mounjaro$39$54,04550 claims
GSKTrelegy Ellipta, Anoro Ellipta$91$38,18068 claims
AstraZenecaFarxiga$40$17,28918 claims
AbbVieLinzess, Synthroid$33$13,44059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Salem

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →